Reproductive medicine exists at a complex intersection of science, politics, contemporary technology, and individual hope. As embryology equipment and laboratory methods continue to advance, the number of treatments has increased, but this expansion has also sparked new discussions about supervision, equity, and the long-term outcomes. Today’s clinics operate within a framework that seeks to safeguard patient safety while still encouraging innovation. In addition to national standards, daily decisions made by physicians, researchers, and lab directors also influence the development of the discipline.
Dr. Zaher Merhi has built a career that connects clinical practice, laboratory management, and reproductive endocrinology research within that context. Born in Lebanon on August 19, 1976, he received board certifications in Obstetrics and Gynecology, Reproductive Endocrinology and Infertility, and High-Complexity Laboratory Direction after receiving training in the United States. His strategy as the Rejuvenating Fertility Center (RFC)’s founder and medical director was influenced by these three specialties. His work puts him directly at the meeting point of patient treatment, lab decision-making, and program design.
Throughout his career, Merhi has focused primarily on clinical outcomes and lab quality. He began his REI fellowship at Albert Einstein College of Medicine and Montefiore Medical Center after completing his OB-GYN residency at Maimonides Medical Center in Brooklyn. He was exposed to research committees, institutional supervision procedures, and training programs while working at Albert Einstein, the University of Vermont, New York University Grossman School of Medicine, and SUNY Downstate Health Sciences University. He oversaw curriculum, supervision, and accreditation criteria while leading SUNY Downstate’s ACGME-accredited REI fellowship, which also added an administrative and regulatory component to his clinical practice.
Guidelines on data integrity, embryo culture conditions, and stimulation methods form the foundation of the governance framework in reproductive medicine. In this regard, Merhi’s HCLD accreditation demonstrates his commitment to ensuring accountability for high-complexity laboratory operations, including environmental monitoring, equipment calibration, gamete and embryo chain of custody, and standard operating procedures. He oversaw research and development of IVF technology at New Hope Fertility Center for a total of around 5 years. Later, at RFC, he worked with systems that depend on institutional review procedures, external proficiency testing, and internal audits to track results and consistency.
At RFC and in his prior positions, patient-facing care follows a standardized process that starts with a thorough intake and risk assessment. Complex histories are common in women with reduced ovarian reserve, metabolic problems, or previous treatment failures. In these situations, treatment regimens typically involve lengthy counseling of available possibilities, such as conventional IVF, moderate or natural stimulation procedures, and experimental methods like intraovarian platelet-rich plasma (PRP) injections. When therapies are still being studied, informed consent is generally a continuous process rather than a single document. Explanations of success rates and the need for longer-term data are often balanced with discussions on advantages, constraints, and alternatives, as documented in his research and public remarks.
Merhi’s laboratory oversight connects to his interest in reproducibility and continuous improvement. Standard operating procedures for specimen handling and validation are central to this work. Environmental and equipment monitoring programs, staff competency assessments, and incident review mechanisms shape how the lab responds to deviations or errors. Traceability is emphasized in data collection and documentation procedures in publications on PRP, endometrial receptivity, and ovarian response in women with poor reserve. These procedures often include precise inclusion criteria, well-defined objectives, and open reporting of results and limitations.
More than 100 peer-reviewed articles on clinical and fundamental scientific subjects have been written by Merhi. Follicular development and anti-Müllerian hormone were the main topics of his early research on ovarian function. Later, he investigated the wider connections between metabolic health and fertility, including conditions such as polycystic ovarian syndrome, advanced glycation end products, bariatric surgery, and obesity. These studies have provided significant insights to public health discussions by linking reproductive outcomes to lifestyle and systemic health. Additionally, he has investigated other ways of ovulation suppression, intraovarian and intrauterine PRP, and nasal human menopausal gonadotropins. Improving choices for women with reduced ovarian reserve or older maternal age has been the focus of much of this study.
In locations where his work has drawn criticism, governance issues have occasionally surfaced. Patients’ interest in PRP-based “ovarian rejuvenation” and other experimental treatments has sparked discussion in the profession. Some studies suggest potential benefits in certain populations, while others recommend more comprehensive, controlled trials. His participation in spindle transfer mitochondrial replacement therapy (MRT) put him at the center of continuing debates over patient autonomy, ethics, and regulations. When laws pertaining to IVF access changed, he also assisted patients in transferring embryos across state lines. These incidents highlight the continuous conflict between increasing patient options and making sure that therapies remain within moral and legal bounds.
Merhi’s governance profile also includes mentorship and education. He has helped train REI professionals in clinical treatment and research techniques as a fellowship director and faculty member. Case conferences, simulation exercises, and audit feedback loops address procedures, documentation, communication, and uncertainty management. His editorial board positions at publications including Nutrients, Reproductive Biology and Endocrinology, and The Journal of Clinical Endocrinology & Metabolism take this educational influence into the peer-review process, where study design, ethical reporting, and data presentation are assessed.
His career has consistently involved training and teaching. He now has a useful method for addressing communication gaps and ambiguity in clinical practice thanks to case reviews, lab simulations, documentation workshops, and audit cycles. The peer review process is further impacted by his editorial roles at publications including Nutrients, Reproductive Biology and Endocrinology, and The Journal of Clinical Endocrinology & Metabolism. There, he has focused on assessing scientific reporting clarity, data quality, and research design.
Additionally, Merhi has made contributions to associations for professionals. In addition to serving as an oral board examiner in reproductive endocrinology for the American Board of Obstetrics and Gynecology (ABOG), he headed the Physician Scientists Special Interest Group (PSSIG) at the American Society for Reproductive Medicine (ASRM) from 2019 to 2020. His continued participation in competitive grant programs, conferences, and scientific submissions that go beyond regular clinical obligations is demonstrated by awards like the Ferring Research Grant, the Bayer Discovery and Innovation Grant, and the ASRM Star Award. He was awarded the ASRM Star Award for several years in a row.
The field faced additional difficulties as a result of the COVID-19 epidemic. Merhi created portable IVF incubator systems that allowed gametes and embryos to be safely transferred between residences, satellite locations, and central labs in response to clinic closures and travel limitations. During the epidemic, he conducted studies that highlighted notable racial inequities in reproductive care. He discovered that Black women had poorer vaccine uptake and greater rates of treatment postponement, suggesting more significant structural and financial barriers. These results contributed to more general conversations regarding access to fertility services, faith in the healthcare system, and the role clinics play in reducing inequality.
Looking ahead, Merhi’s work in stem cell-based approaches, low-level laser therapy (LLLT), and artificial intelligence (AI) in embryo assessment suggests that governance concerns will likely remain important in his work. Concerns about patient privacy and the handling of large clinical datasets arise from the need to evaluate new technologies through organized pilots, establish important performance measures, and conduct long-term follow-up. Frameworks centered on standards, training, and data discipline are expected to dictate which therapies become standard practice as reproductive care continues to rely on digital technologies and sophisticated lab procedures.
Dr. Zaher Merhi’s career offers one perspective on how a single clinician-scientist functions both within and outside established systems. He has contributed to the development of the laws and procedures governing contemporary fertility care through his positions in teaching, research, laboratory management, and professional associations. He places special emphasis on patient safety, openness, and continuous assessment of new treatments.
Disclaimer: The information provided in this article is for informational purposes only and should not be construed as medical advice. Always consult with a qualified healthcare professional before making any decisions related to your reproductive health or treatment options. The content in this article is not intended to diagnose, treat, or cure any medical conditions.
